Articles related to ACUTE MYELOID LEUKEMIA (AML)

Ipsen voluntarily withdrew tazemetostat in follicular lymphoma and epithelioid sarcoma after 18 of 318 SYMPHONY-1 participants developed hematologic second primary malignancies, including three deaths.

DAGO2 produced 3-year overall survival of 52% versus 35% with CPX-351 in older patients with non-adverse-risk AML in a 439-patient randomized comparison.

The study introduced an ML-based, tunable risk stratification strategy tailored for AML patients treated with venetoclax plus azacitidine. By addressing real-world data limitations and incorporating diverse diagnostic features, the approach enables more accurate and adaptable prognostic modeling than traditional systems, supporting personalized treatment decisions and broader clinical applicability.

To help patients and clinicians in strategizing about care decisions at the individual level, ASH convened a multidisciplinary panel — which included experts and patient representatives — to form standardized guidelines for newly diagnosed AML in older patients.

Final analysis confirms venetoclax plus modified intensive chemotherapy achieves durable remissions with 17.9-month treatment-free intervals in fit elderly AML patients, particularly those with de novo disease.

Flow cytometric evaluation of MRD in AML demonstrates that blast phenotypes consistently show abnormalities but may evolve during treatment, emphasizing the importance of comprehensive antigen panel analysis for accurate detection.